Incretin Atlas › Trials › STEP-HFpEF
STEP-HFpEF
Semaglutide · HFpEF + obesity
Design
- Molecule(s)
- Semaglutide
- Population
- HFpEF + obesity
- Official title
- Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2021-03 → 2023-04
- Participants
- 529
- Duration
- 52 weeks
- Registry
- NCT04788511
Outcomes in the indication
STEP-HFpEF Semaglutide · HFpEF + obesity · 52 weeks · n = 529 seed
KCCQ-CSS +7.8 points vs placebo; weight −13.3 % vs −2.6 %
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Body weight, percent change from baseline week 52 | −13.3 | −2.6 | −10.7 (−11.9 to −9.4) percentage points | verified |
| KCCQ clinical summary score, change from baseline week 52 | +16.6 | +8.7 | +7.8 (+4.8 to +10.9) points (0-100) | verified |
Verbatim quotes (2)
- Body weight, percent change from baseline
the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001)
- KCCQ clinical summary score, change from baseline
The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP-HFpEF. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.